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Background and purpose: We aimed to estimate the prevalence of perceived
cognitive impairment (PCI) and explore its associations with lifestyle and dis-
ease characteristics in a large international cohort of people with multiple scle-
rosis (MS).
Methods: This study was a cross-sectional analysis. Participants rated their
cognitive function over the preceding 4 weeks using four questions in a sub-
scale within the Multiple Sclerosis Quality of Life questionnaire (MSQOL-54).
These questions assessed perceived concentration, attention and memory by
the patient and family/friends. Four deﬁnitions of PCI were derived, ranging
from lowest to highest speciﬁcity. Associations with PCI were assessed by log-
binomial regression.
Results: The prevalence of PCI in our sample ranged from 41.0% (95% con-
ﬁdence interval, 39.0–43.0) using the least-speciﬁc deﬁnition to 11.6% (95%
conﬁdence interval, 10.3–12.9) using the most speciﬁc deﬁnition. A number of
factors were associated with PCI, increasing in magnitude as the deﬁnition
speciﬁcity increased, including positive associations for smoking and body
mass index, whereas physical activity, dietary quality and use of vitamin D/
omega-3 supplements were inversely associated with PCI.
Conclusions: Our study reports associations between healthy lifestyle beha-
viours and PCI in people with MS. Although reverse causality is a potential
explanation for our ﬁndings, previous studies have shown comparable associa-
tions with healthy lifestyle and MS onset and progression. Subject to external
validation, these results suggest beneﬁts realized from a healthy lifestyle in
people with MS.
Introduction
Cognitive impairment is seen in 40–60% of people
with multiple sclerosis (MS) depending on deﬁnitions
and measurement tools [1]. It occurs more commonly
in males [2] and is frequently under-diagnosed [3,4].
Cognitive impairment includes deﬁcits in complex
attention, executive functioning, information process-
ing eﬃciency and speed, and long-term memory [2,5–
7]. These disabilities can negatively aﬀect quality of
life, employment, education and home life [5]. This is
particularly relevant in younger adults with many
competing pressures in work and family life [7]. Cog-
nitive impairment and processing speed may be
related to the severity and type of MS, i.e. those with
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greater disease progression are more likely to manifest
cognitive symptoms, as well as diﬀerences between the
relapsing-remitting and progressive MS types [6]. Per-
ceived cognitive impairment (PCI) is important in
itself, being a major determinant of health-related
quality of life and work outcomes [8,9]. Additionally,
self-reported cognitive measures can indicate objective
cognitive impairment in people with MS [10].
Accurately assessing the prevalence of PCI is diﬃ-
cult, given the variability in how it is deﬁned, either
by longitudinal in-clinic assessment or by participant
self-reporting symptoms [1]. Treating cognitive impair-
ment in MS is also complex, with pharmacological
treatments showing little eﬃcacy in treating or pre-
venting cognitive symptoms. Beyond disease-modify-
ing drugs, an additional strategy may be modiﬁcation
of lifestyle such as physical activity, better diet and
avoiding behaviours such as smoking, given their
strong protective association against age-related cogni-
tive decline in the general population [11]. Lifestyle
factors such as diet, body mass index (BMI), smoking,
physical activity and meditation have been associated
with MS onset [12,13], as well as general health [14–
16], suggesting potential for secondary prevention
through lifestyle modiﬁcation.
This study aimed to estimate the prevalence of PCI
in a large international sample of people with MS and
to explore associations between lifestyle and other fac-
tors with PCI.
Methods
Participants and data collection
Participants were enrolled in the HOLISM study for
which methodology has previously been described [17].
Brieﬂy, participants were recruited via online platforms
and SurveyMonkey was used to provide respondents
with a participant information sheet, consent indicator
and survey. Inclusion criteria required participants to
be at least 18 years old and self-reporting a physician
diagnosis of MS. The Health Sciences Human Ethics
Sub-Committee at the University of Melbourne pro-
vided ethical approval (Ethics ID: 1545102) and all par-
ticipants provided informed consent.
Data collected and tools used
A range of demographic, lifestyle and clinical parame-
ters were queried using validated tools, where possible,
as described previously [17], including sun exposure,
vitamin D and omega-3 supplement use, biometrics for
calculation of BMI and meditation frequency, among
others. Physical activity was assessed by the
International Physical Activity Questionnaire [18]. Diet
was assessed using the Diet Habits Questionnaire, from
which an overall diet quality score ranging from 0 to
100 was calculated [19]. Disability was assessed using
the Patient-Determined Disease Steps (PDDS) scale
[20], which has been validated against the Expanded
Disability Status Scale and from which the disease
duration-adjusted Patient-Derived Multiple Sclerosis
Severity Score (P-MSSS) was calculated [21]. Fatigue
was assessed using the Fatigue Severity Scale [22].
Perceived cognitive impairment measure
A subscale within the Multiple Sclerosis Quality of
Life questionnaire (MSQOL-54) was used to assess
cognitive function [23]. This is an interval scale based
on the following four questions.
1 Have you had diﬃculty concentrating and thinking?
2 Did you have trouble keeping attention on an activ-
ity for long?
3 Have you had trouble with your memory?
4 Have others, such as family members or friends,
noticed that you have trouble with your memory or
problems with your concentration?
Respondents indicated how much of the time in the
previous 4 weeks they had experienced each symptom
(1 representing all of the time and 6 representing none
of the time). We evaluated four deﬁnitions of PCI,
ranging from those with at least one of the four
MSQOL cognition-related parameters ‘a good bit of
the time’, ‘most of the time’ or ‘all of the time’ to hav-
ing all four parameters. Given the poorer speciﬁcity of
the deﬁnition requiring one parameter and the poorer
sensitivity of the deﬁnition requiring all four parame-
ters, we further examined the middle two deﬁnitions,
requiring at least two or at least three parameters.
Statistical analysis
Predictors of PCI were assessed by log-binomial regres-
sion, estimating a prevalence ratio. The primary adjusted
model included adjustment for confounders identiﬁed
from previous literature [1], i.e. age, sex, level of educa-
tion completed and level of disability as measured by P-
MSSS, except that of disease duration, which was
adjusted for PDDS score. All analyses were conducted
in STATA/SE 15.0 (Statacorp, College Park, TX, USA).
Results
The total cohort of 2464 participants was largely
female (82.3%), with a mean age of 45.5 years and
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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median PDDS score of 3.0. The cohort generally
engaged in healthy behaviours, 58.8% engaging in at
least moderate physical activity, only 11.7% smoked
tobacco and supplement use was frequent. Apart from
a smaller proportion from North America and partici-
pants who were single, no covariates signiﬁcantly dif-
fered between those who completed the MSQOL-54
cognition-related questions (n = 2314) and those who
did not (n = 150, Table S1).
Distribution and determinants of perceived cognitive
impairment (all definitions)
Perceived cognitive impairment decreased from 41.0%
(95% conﬁdence interval, 39.0–43.0) using the lowest
speciﬁcity measure to 11.6% (95% conﬁdence interval,
10.3–12.9) using the most speciﬁc measure (Table S2).
A number of factors were signiﬁcantly associated
with PCI, more with the less speciﬁc deﬁnition and
fewer with the more stringent deﬁnitions of the out-
come. Some of these, such as age and education, both
associated with signiﬁcantly lower frequency of PCI,
may reﬂect participation and measurement biases. The
signiﬁcant associations of disease-related parameters,
such as relapse rate, disability and fatigue, with
greater frequency of PCI probably reﬂected covari-
ance with greater disease activity.
Prevalent depression risk was also positively associ-
ated with PCI, whereas a greater number of social
supports or being partnered were associated with a
lower frequency of PCI. Multiple behavioural factors
were signiﬁcantly associated with PCI, including posi-
tive associations with smoking and BMI, and inverse
associations with physical activity, dietary quality,
supplement use and alcohol intake, as well as less con-
sistent associations with meditation.
Determinants of perceived cognitive impairment (third-
and second-most specific definitions)
The middle two deﬁnitions of PCI, those requiring at
least two or at least three cognitive symptoms from the
MSQOL-54, were evaluated further by adjustment for
age, sex, education, P-MSSS and whether participants
had ongoing symptoms from a relapse in the preceding
30 days (Table 1). Some, such as age and education
were generally robust to adjustment, indicating inde-
pendent eﬀects. The associations of physical activity,
BMI, alcohol intake, diet and supplement use were lar-
gely independent of age, sex, education and disability,
whereas the association of smoking was attenuated by
about 25% on adjustment, although still signiﬁcant.
The association of meditation, weak and inconsistent
alone, was greatly reduced on adjustment, whereas the
association of better diet was generally robust to adjust-
ment. Disease-speciﬁc qualities, such as relapse fre-
quency, disease trajectory and fatigue, were also largely
robust to adjustment, substantiating the interpretation
that these associations reﬂect more active disease being
more likely to manifest as PCI. Adjusted associations
of BMI (Fig. 1), dietary quality (Fig. 2) and smoking
and supplement use (Fig. 3) are also shown graphically,
demonstrating the comparability between the two deﬁ-
nitions, but also showing the increase in magnitude
with little increase in error as speciﬁcity is increased.
Further adjustment for prevalent depression risk and
fatigue attenuated but did not attenuate most associa-
tions, except for instances where the predictor was on a
similar causal pathway, e.g. BMI and physical activity
(attenuated on adjustment for fatigue) and marital sta-
tus, number of social supports and alcohol intake (at-
tenuated on adjustment for depression risk).
Discussion
The PCI prevalence estimates ranged from 41% using
the lowest speciﬁcity deﬁnition to 11.6% using the
highest speciﬁcity deﬁnition. Although this measure is
not an objective clinical assessment of cognitive
impairment, it is nonetheless an important outcome,
in both the context of its potential indication of clini-
cal cognitive impairment and reﬂecting the patient’s
perception of cognitive dysfunction, which is relevant
in joint patient–practitioner decision-making. We
found associations of multiple lifestyle and clinical
covariates with PCI, increasing in magnitude and sig-
niﬁcance as deﬁnition speciﬁcity increased, suggesting
true associations. Not all factors were causal in nat-
ure, however, and may instead reﬂect measurement/
participation biases. However, many factors were
strong candidates for causal relationships, including
smoking, physical activity, BMI, dietary quality and
vitamin D and omega-3 supplement use.
Defining perceived cognitive impairment and
prevalence estimate comparisons
Current neuropsychological tests for people with MS
are time-consuming, require specialist training and are
often administered face to face, leading to potential
under-diagnosis [3]. Subjective reporting of PCI has
been shown to correlate with objective testing in some
studies [24], but not in others [25,26]. However, surro-
gate or self-reported markers for cognitive impairment
are frequently used in epidemiological studies.
To assess PCI, we utilized four deﬁnitions, ranging
from having frequent cognitive symptoms in one
domain of the MSQOL-54 to having them in all four.
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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(a) (b)
Figure 2 Association of diet quality score (higher score indicates more healthy diet quality) with perceived cognitive impairment by (a)
third-most and (b) second-most speciﬁc deﬁnitions. Coeﬃcients adjusted for age, sex, education and Patient-Determined Multiple
Sclerosis Severity Score. CI, conﬁdence interval; PR, prevalence ratio.
(a) (b)
Figure 1 Association of body mass index (BMI) with perceived cognitive impairment by (a) third-most and (b) second-most speciﬁc
deﬁnitions. Coeﬃcients adjusted for age, sex, education and Patient-Determined Multiple Sclerosis Severity Score. CI, conﬁdence inter-
val; PR, prevalence ratio.
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Although results using all four deﬁnitions are pre-
sented, the deﬁnitions that we regard as most appropri-
ate balance the needs of speciﬁcity and sensitivity,
namely the second- and third-most speciﬁc, which esti-
mate prevalences of 24.3% and 33.1% respectively. The
reason for selecting these deﬁnitions was twofold: ﬁrst,
we aimed to maximize speciﬁcity and sensitivity, and
secondly, by examination of the proportions with PCI
between deﬁnitions and the change in coeﬃcients, there
was a good reason to select the second-most speciﬁc
measure. However, we have also presented results for
the third-most speciﬁc deﬁnition.
Julian et al. assessed PCI in moderately depressed
patients with MS using the four-item cognitive scale of
the MSQOL-54, as we have done, using participant
responses to produce a ‘Subjective Cognitive Impair-
ment Index’ [26]. The study showed that depression
confounded the association between subjective and
objective scores of PCI, but for those whose depression
lifted following treatment, the concordance between
this subjective score and formal neuropsychiatric test-
ing of cognitive function was reasonable. Similarly,
Deloire et al used the same four items from a French
adaptation of the MSQOL-54, ﬁnding that depression
and fatigue were more predictive of PCI [27]. Both
studies, however, had only small sample sizes and were
thus signiﬁcantly limited in comparison with our study.
A much larger study, the NARCOMS study, con-
taining information from over 35 000 people with MS,
examined cognition as one of 11 domains commonly
aﬀected in MS [28]. They used a self-reported tool sim-
ilar to the MSQOL-54, assessing PCI by disease dura-
tion; at one end of the spectrum (disease duration
≤1 year), the prevalence estimate of PCI was approxi-
mately 25–30% and, at the other end of the spectrum
(disease duration 29–30 years), PCI prevalence was
approximately 50%. In our sample, although our
participants had a lower mean disease duration
(8.7 years), we estimated similar PCI prevalence esti-
mates, about 22.5% and 32% using the second- and
third-most speciﬁc deﬁnitions. This provides some
external support for our mode of assessing PCI, realiz-
ing similar proportions using analogous methods.
Perceived cognitive impairment determinants
Some of the factors signiﬁcantly associated with PCI
were probably not causal in nature but rather reﬂected
Figure 3 Association of tobacco and supplement use with perceived cognitive impairment by third-most and second-most speciﬁc deﬁ-
nitions. Coeﬃcients adjusted for age, sex, education and Patient-Determined Multiple Sclerosis Severity Score. CI, conﬁdence interval;
PR, prevalence ratio.
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selection or participation biases. For instance, the
inverse association of older age with PCI probably
reﬂects diﬀerential participation with age. Some fac-
tors examined may have been modulators of response
to the questions posed. For instance, the inverse asso-
ciation of higher education with PCI probably
reﬂected the impact of greater educational exposure
with the memory and attention queried. The associa-
tions of disease-speciﬁc parameters, such as relapse
number or disease trajectory, probably reﬂected corre-
lation of disease activity with PCI.
Other factors may have legitimate relationships with
PCI. Smoking and BMI showed consistent and signiﬁ-
cant deleterious associations with PCI, increasing in
magnitude with deﬁnition speciﬁcity. On the contrary,
beneﬁcial behaviours, such as physical activity, dietary
quality and vitamin D and omega-3 supplement use,
showed signiﬁcant inverse associations with PCI,
enhancing with increased speciﬁcity. However, the
potential for reverse causality is an issue with all of
these determinants, especially in a cross-sectional anal-
ysis. Greater social support showed a signiﬁcant and
robust inverse association with PCI, although there
was also a potential for reverse causality here. Also,
there was the potential that diﬀerential social environ-
ments might impact upon the measurement of PCI
used, such that those with fewer contacts might not
recognize cognitive changes as early.
A recent study of over 2000 older participants from
the general population showed that, after adjusting for
age, sex and comorbidities, physical activity, healthy
diet and light-to-moderate alcohol consumption were
all associated with better cognitive function [29], in keep-
ing with our ﬁndings. An intervention study published
in 2017 showed promise for lifestyle modiﬁcations,
where people with MS reported less fatigue, improved
mood and cognitive function following a 12-month mul-
timodal lifestyle modiﬁcation programme [24].
Strengths and limitations
In this large, multinational web-based study, we made
use of self-reported exposure and clinical outcome data.
Some of these, like the PDDS score and P-MSSS, have
been validated against in-clinic measures. We acknowl-
edge that we lacked an objective clinical cognitive
impairment measure with which to compare, as this
was not logistically feasible given the study design.
However, our ﬁndings have considerable importance
for self-perceived cognitive function in people with MS
and our data indicate the extent to which this cohort
perceives diﬃculties in cognitive functioning. Our anal-
yses show that lifestyle factors may play an important
role in addressing these perceived diﬃculties.
Deﬁning PCI is a complex process, particularly via
self-report-based questionnaire methods like those
employed here or elsewhere [26–28]. Although the use
of MSQOL-54 and related self-reported questionnaire
methods is a promising mode of assessing PCI in large
cohort studies, this method should be validated against
standard clinical measures. Also, these results are based
on a cross-sectional study design and therefore causal
directionality cannot be ascribed. Although external
consistency with the results of other studies adds weight
to our ﬁndings, replication, ideally in a prospective
cohort study design, is required before any guidance
can be inferred from these results. We also cannot rule
out the possibility that symptoms of cognitive impair-
ment could be due to non-MS pathology, such as
stroke, trauma or other processes. Finally, our study is,
like many observational cohort studies, susceptible to
healthy participant bias. There is also an unknown pro-
portion of potential participants who may not have
participated due to perceived or diagnosed cognitive
impairment. Thus, our estimates of the prevalence of
PCI may be underestimates.
Conclusions
These results show that the prevalence estimate of
PCI in this sample ranged from 11.6% to 41.0%.
These results add to the literature, which suggests that
cognitive impairment is a signiﬁcant issue in the MS
clinical course that should be studied further. Our
data showed PCI to be strongly associated with the
modiﬁable risk factors smoking, diet and obesity, after
adjusting for other relevant demographic and clinical
covariates. Although reverse causality is a potential
explanation of our results, many of the identiﬁed sig-
niﬁcant covariates have been previously associated
with MS onset and progression. Modiﬁcation of risk
factors such as smoking, diet and obesity may form
the basis of a secondary preventive approach to pre-
venting and managing PCI in people with MS.
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